Juno Ends JCAR015 Development In ALL, Cementing Third Place CAR-T Position
Executive Summary
Juno and partner Celgene closed the ROCKET study for JCAR015, which has been on clinical hold since November, and ended development in ALL in favor of its new and improved CD19-targeting CAR-T therapies.
You may also be interested in...
Can China Ace The CAR-T Race?
Helped by Nanjing Legend's multimillion dollar deal with J&J, China has now overtaken the US in number of clinical trials using CAR-T cell approaches to treating cancers, but could uncertainties derail the country's CAR-T train from steaming ahead?
The Next Challenge: Improving And Predicting Responses As CAR-T Therapies Advance
Chimeric antigen receptor T cell (CAR-T) therapies have shown unprecedented response rates and may extend survival for patients expected to live only a few more months. Now, CAR-T developers are looking at how to improve responses, extend survival and improve safety.
Celgene's CAR-T Leadership Goals Advance At ASH 2017
Celgene's partnership strategy paid off at ASH with positive results for two CAR-T therapies in development with bluebird bio and Juno. The company is pursuing first- and best-in-class opportunities with the goal of becoming a leader in the CAR-T field.